Person: Kolossa-Gehring, Marike
Lade...
E-Mail-Adresse
Geburtsdatum
Forschungsvorhaben
Organisationseinheiten
Berufsbeschreibung
Biologin
Toxikologin
Toxikologin
Nachname
Kolossa-Gehring
Vorname
Marike
Name
6 Ergebnisse
Suchergebnisse
Gerade angezeigt 1 - 6 von 6
Veröffentlichung Deutsche Umweltstudie zur Gesundheit von Kindern und Jugendlichen 2014-2017 (GerES V)(Umweltbundesamt, 2023) Hahn, Domenica; Kolossa-Gehring, Marike; Lange, Rosa; Lemke, Nora; Murawski, Aline; Peisker, Jasmin; Debiak, Malgorzata; Rucic, Enrico; Zimmermann, Philipp; David, Madlen; Gerofke, Antje; Weber, Till; Pack, Kim LauraIn der Deutschen Umweltstudie zur Gesundheit (GerES) wird die Schadstoff-Belastung der Bevölkerung repräsentativ für die Menschen in Deutschland erhoben. In der fünften Erhebung, GerESV (2014-2017), wurden 2.294 Kinder und Jugendliche im Alter von 3 bis 17 Jahren aus 167 Orten in ganz Deutschland untersucht. GerES V ist eine bevölkerungsrepräsentative Querschnittstudie und wurde in enger Kooperation mit der "Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland" (KiGGS Welle 2) des Robert-Koch-Instituts durchgeführt. Im Human-Biomonitoring (HBM) von GerESV wurden 107 verschiedene Substanzen im Blut bzw. Urin der Teilnehmenden gemessen. Der vorliegende Bericht fasst die HBM-Ergebnisse von GerESV zusammen. Bei Vorliegen entsprechender Beurteilungswerte wird eine gesundheitliche Bewertung vorgenommen. Der Bericht gibt einen Überblick über die Abläufe der Datenerhebung und die chemisch-analytischen und statistischen Methoden. Die wichtigsten Ergebnisse zu Belastungsquellen und -pfaden sowie besonders belasteten Bevölkerungsgruppen sind zusammengefasst und in aggregierter Form tabellarisch präsentiert. Für jede untersuchte Substanz werden außerdem die Quellen, die toxikologischen Eigenschaften und aktuellen Regulationen aufgeführt. Die bisherige Nutzung der Daten aus GerES V für Politik- und Öffentlichkeitsarbeit sowie in internationalen Kooperationen ist ebenfalls dargelegt. Quelle: ForschungsberichtVeröffentlichung HBM4EU results support the Chemicals' Strategy for Sustainability and the Zero-Pollution Action Plan(2023) Vicente, Joana Lobo; David, Madlen; Ganzleben, Catherine; Gasol, Roser; Gerofke, Antje; Kolossa-Gehring, MarikeOne of the major goals of the European Human Biomonitoring Initiative (HBM4EU) was to bridge the gap between science and policy by consulting both policy makers and national scientists and generating evidence of the actual exposure of residents to chemicals and whether that exposure would be suggest a potential health risk. Residents' perspectives on chemical exposure and risk were also investigated. HBM4EU's research was designed to answer specific short-term and long-term policy questions at national and European levels, and for its results to directly support regulatory action on chemicals. A strategy was established to prioritise chemicals for analysis in human matrices, with a total of 18 substances/substance groups chosen to be investigated throughout the five-and a -half-year project. HBM4EU produced new evidence of human exposure levels, developed reference values for exposure, investigated determinants of exposure and derived health-based guidance values for those substances. In addition, HBM4EU promoted the use of human biomonitoring data in chemical risk assessment and developed innovative tools and methods linking chemicals to possible health impacts, such as effect biomarkers. Furthermore, HBM4EU advanced understand of effects from combined exposures and methods to identify emerging chemicals. With the aim of supporting policy implementation, science-to-policy workshops were organised, providing opportunities for joint reflection and dialogue on research results. I, and indicators were developed to assess temporal and spatial patterns in the exposure of European population. A sustainable human biomonitoring monitoring framework, producing comparable quality assured data would allow: the evaluation of time trends; the exploration of spatial trends: the evaluation of the influence of socio-economic conditions on chemical exposure. Therefore, such a framework should be included in the European Chemicals' Strategy for Sustainability and the data would support the Zero Pollution Action Plan. © 2023 The AuthorsVeröffentlichung A walk in the PARC: developing and implementing 21st century chemical risk assessment in Europe(2023) Marx-Stoelting, Philip; Bandow, Nicole; Rivière, G.; Kolossa-Gehring, Marike; Luijten, MirjamCurrent approaches for the assessment of environmental and human health risks due to exposure to chemical substances have served their purpose reasonably well. Nevertheless, the systems in place for different uses of chemicals are faced with various challenges, ranging from a growing number of chemicals to changes in the types of chemicals and materials produced. This has triggered global awareness of the need for a paradigm shift, which in turn has led to the publication of new concepts for chemical risk assessment and explorations of how to translate these concepts into pragmatic approaches. As a result, next-generation risk assessment (NGRA) is generally seen as the way forward. However, incorporating new scientific insights and innovative approaches into hazard and exposure assessments in such a way that regulatory needs are adequately met has appeared to be challenging. The European Partnership for the Assessment of Risks from Chemicals (PARC) has been designed to address various challenges associated with innovating chemical risk assessment. Its overall goal is to consolidate and strengthen the European research and innovation capacity for chemical risk assessment to protect human health and the environment. With around 200 participating organisations from all over Europe, including three European agencies, and a total budget of over 400 million euro, PARC is one of the largest projects of its kind. It has a duration of seven years and is coordinated by ANSES, the French Agency for Food, Environmental and Occupational Health & Safety. © The Author(s) 2023Veröffentlichung How to use human biomonitoring in chemical risk assessment: methodological aspects, recommendations, and lessons learned from HBM4EU(2023) Santonen, Tiina; Mahiout, Selma; Apel, Petra; Alvito, Paula; Kolossa-Gehring, Marike; Gerofke, Antje; Lange, RosaOne of the aims of the European Human Biomonitoring Initiative, HBM4EU, was to provide examples of and good practices for the effective use of human biomonitoring (HBM) data in human health risk assessment (RA). The need for such information is pressing, as previous research has indicated that regulatory risk assessors generally lack knowledge and experience of the use of HBM data in RA. By recognising this gap in expertise, as well as the added value of incorporating HBM data into RA, this paper aims to support the integration of HBM into regulatory RA. Based on the work of the HBM4EU, we provide examples of different approaches to including HBM in RA and in estimations of the environmental burden of disease (EBoD), the benefits and pitfalls involved, information on the important methodological aspects to consider, and recommendations on how to overcome obstacles. The examples are derived from RAs or EBoD estimations made under the HBM4EU for the following HBM4EU priority substances: acrylamide, o-toluidine of the aniline family, aprotic solvents, arsenic, bisphenols, cadmium, diisocyanates, flame retardants, hexavalent chromium [Cr(VI)], lead, mercury, mixture of per-/poly-fluorinated compounds, mixture of pesticides, mixture of phthalates, mycotoxins, polycyclic aromatic hydrocarbons (PAHs), and the UV-filter benzophenone-3. Although the RA and EBoD work presented here is not intended to have direct regulatory implications, the results can be useful for raising awareness of possibly needed policy actions, as newly generated HBM data from HBM4EU on the current exposure of the EU population has been used in many RAs and EBoD estimations. © 2023 The Author(s)Veröffentlichung Human biomonitoring in health risk assessment in Europe: Current practices and recommendations for the future(2019) Louro, Henriqueta; Heinälä, Milla; Bessems, Jos; Kolossa-Gehring, MarikeHuman biomonitoring (HBM) is an important tool to survey the internal exposure of humans which represents the real life chemical body burden to chemicals and/or their metabolites. It results from total exposure to chemical substances from different sources and via different routes. These substances may be regulated under different legislative frameworks on chemicals (e.g., environmental, occupational, food safety etc). In occupational health, HBM has long traditions to control the exposures at workplaces. By providing accurate data on internal exposure, HBM data can improve human health risk assessment (RA) for both the general population and workers. Although the past few years have shown good examples on the use of HBM in the RA of chemicals, there is still quite some work to be done to improve its use in a regulatory RA. Under the scope of the European Human Biomonitoring Initiative (project HBM4EU, 2017-2021), the current study reviews the state-of-the-art of HBM use in chemicals RA with a special focus in Europe, and attempts to identify hurdles and challenges faced by regulators. To gather information on the use of HBM, including the availability of guidance on how to use it in RA, the RA schemes applied by different European or international organizations were analysed. Examples of such use were identified for a few selected groups of chemicals of concern for human health. In addition, we present the results of a survey, aimed at collecting information from national regulatory risk assessors on their day-to-day RA practices, the use of HBM data, and the obstacles and challenges related to their use. The results evidenced and explained some of the current obstacles of using HBM data in RA. These included the lack of HBM guidance values or biomonitoring equivalents (BEs), limited toxicokinetic information to support the interpretation of HBM data and, in the occupational health and safety (OSH) field, the lack of legal enforcement. Therefore, to support the integration of HBM in regulatory RA, we recommend, on one hand, the elaboration of a EU level guidance on the use of HBM in RA and, on the other hand, the continuation of research efforts to integrate HBM with new RA approaches using in vitro/in silico data and Adverse Outcome Pathways (AOPs). © 2019 The Authors. Published by Elsevier GmbH.Veröffentlichung Conducting evaluations of evidence that are transparent, timely and can lead to health-protective actions(2022) Chartres, Nicholas; Sass, Jennifer B.; Gee, David; Kolossa-Gehring, MarikeBackground: In February 2021, over one hundred scientists and policy experts participated in a web-based Workshop to discuss the ways that divergent evaluations of evidence and scientific uncertainties are used to delay timely protection of human health and the environment from exposures to hazardous agents. The Workshop arose from a previous workshop organized by the European Environment Agency (EEA) in 2008 and which also drew on case studies from the EEA reports on "Late Lessons from Early Warnings" (2001, 2013). These reports documented dozens of hazardous agents including many chemicals, for which risk reduction measures were delayed for decades after scientists and others had issued early and later warnings about the harm likely to be caused by those agents. Results: Workshop participants used recent case studies including Perfluorooctanoic acid (PFOA), Extremely Low Frequency-Electrical Magnetic Fields (ELF-EMF fields), glyphosate, and Bisphenol A (BPA) to explore myriad reasons for divergent outcomes of evaluations, which has led to delayed and inadequate protection of the public's health. Strategies to overcome these barriers must, therefore, at a minimum include approaches that 1) Make better use of existing data and information, 2) Ensure timeliness, 3) Increase transparency, consistency and minimize bias in evidence evaluations, and 4) Minimize the influence of financial conflicts of interest. Conclusion: The recommendations should enhance the production of "actionable evidence," that is, reliable evaluations of the scientific evidence to support timely actions to protect health and environments from exposures to hazardous agents. The recommendations are applicable to policy and regulatory settings at the local, state, federal and international levels. © The Authors